- Home
- REPL vs TLRY Comparison
REPL vs TLRY Comparison
Compare REPL & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- TLRY
- Stock Information
- Founded
- REPL 2015
- TLRY N/A
- Country
- REPL United States
- TLRY Canada
- Employees
- REPL N/A
- TLRY N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- TLRY Medicinal Chemicals and Botanical Products
- Sector
- REPL Health Care
- TLRY Health Care
- Exchange
- REPL Nasdaq
- TLRY Nasdaq
- Market Cap
- REPL 547.0M
- TLRY 624.7M
- IPO Year
- REPL 2018
- TLRY 2018
- Fundamental
- Price
- REPL $5.56
- TLRY $1.03
- Analyst Decision
- REPL Buy
- TLRY Hold
- Analyst Count
- REPL 10
- TLRY 3
- Target Price
- REPL $8.25
- TLRY $1.38
- AVG Volume (30 Days)
- REPL 24.2M
- TLRY 78.6M
- Earning Date
- REPL 08-07-2025
- TLRY 10-09-2025
- Dividend Yield
- REPL N/A
- TLRY N/A
- EPS Growth
- REPL N/A
- TLRY N/A
- EPS
- REPL N/A
- TLRY N/A
- Revenue
- REPL N/A
- TLRY $821,309,000.00
- Revenue This Year
- REPL N/A
- TLRY $8.95
- Revenue Next Year
- REPL $194.05
- TLRY $4.76
- P/E Ratio
- REPL N/A
- TLRY N/A
- Revenue Growth
- REPL N/A
- TLRY 4.10
- 52 Week Low
- REPL $2.68
- TLRY $0.35
- 52 Week High
- REPL $17.00
- TLRY $1.98
- Technical
- Relative Strength Index (RSI)
- REPL 44.05
- TLRY 64.74
- Support Level
- REPL $4.49
- TLRY $0.55
- Resistance Level
- REPL $6.39
- TLRY $1.37
- Average True Range (ATR)
- REPL 0.77
- TLRY 0.12
- MACD
- REPL 0.09
- TLRY 0.05
- Stochastic Oscillator
- REPL 48.77
- TLRY 58.54
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. USA exposure consists of CBD products and alcohol.